MORROW-SODALI
11.5.2021 13:02:09 CEST | Business Wire | Press release
When institutional investors with USD 29 trillion in assets under management were asked what issue was most likely to prompt them to engage with company boards, climate change topped the agenda.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005108/en/
This is among the key findings of the 2021 Institutional Investor Survey by Morrow Sodali, released today.
The annual global poll of over 40 institutional investors aims to find out what is really important for them when analyzing companies, and to highlight their main areas of focus in determining how to exercise their voting rights at ongoing shareholder meetings.
Survey questions are designed to identify the latest trends in company engagement , including ESG (Environmental, Social and Governance ) and sustainability, remuneration and AGM-related issues , and shareholder activism .
The 2021 iteration of the survey, which is now in its 6th year, underscores how the focus on ESG continues to intensify. The institutions surveyed see a clear link between ESG performance and good financial performance, and they want companies to improve their engagement and reporting on these topics.
While these include issues such as board composition, executive remuneration and human capital management, which are all being looked at more closely than ever before, climate change tops the agenda in terms of prompting investors to engage. The survey findings indicate that there is ample room for improvement in the quality of corporate ESG reporting, and investors in particular, want companies to discuss these topics in the context of their business plans. Companies should ensure that they have the right people engaging, in terms of both management and the board, and that these representatives are properly prepared to discuss the relevant issues.
Investors expect to see links between climate change and financial risks and opportunities identified, time horizons of the expected impact of climate change on corporate strategies explained, and metrics, targets and achievements clearly disclosed. With climate risk so clearly at the forefront of investors’ minds, it comes as no surprise that TCFD far outpaced other reporting frameworks as the first choice of 75% of respondents.
The survey highlights a strong uptick in the popularity of TCFD, and many investors now expect companies to either align with it or explain why they believe it is not necessary. SAS3 was the second choice, and it was interesting to see that a large proportion of respondents (39%) reported using in-house proprietary frameworks. This is a message to the market that investors are becoming much more sophisticated in this regard.
The survey revealed that statements of company purpose are considered to be one of the driving forces behind creating sustainable long-term value, with a strong majority (86%) of investor respondents agreeing that every company should disclose its corporate purpose, and a substantial proportion (20%) saying the issue could lead them to vote against the board chair or other directors.
ESG is now firmly established as a key factor in how investors evaluate company strategy and performance, and predictably the overwhelming majority (95%) of respondents wanted to see it incorporated into executive incentive plans. Trends from past years show that investors wanted to see a proportion of incentives tied to sustainability measures, and when drilled down in 2021, the result is a strong consensus (69%) felt that 5–25% was a reasonable amount.
Particularly noteworthy was the response on annual incentives, where the survey showcases a significant upturn in support (95%) for the inclusion of sustainability performance metrics in short-term incentive plans. By comparison, when investors were asked how important they found ESG performance metrics in short-term incentive programs in 2018, 29% said ‘not important’ and an additional 8% had no opinion. This does raise interesting questions around which ESG targets can credibly be included in annual incentives, as that clearly is not the case for all types of metrics.
For the last three years, the Morrow Sodali survey has asked investors: “What would lead you to vote against executive remuneration proposals?’’, and they have consistently indicated “misalignment of pay and performance” to be their primary concern. This year, the survey sought to examine this issue more deeply by asking what they considered the key indicators of such misalignment to be.
In response, investors identified incentive plans without performance hurdles (63%), bonuses paid by companies while severely impacted by COVID-19 (46%) and the adoption of discretionary variable pay programs (29%) as their key concerns.
Shareholder activism continues to evolve in 2021, and the survey reflected growing investor support for activist campaigns, both traditional and ESG-related. While most investors believe engaging with board members is the most effective way to influence boards, collaboration with other shareholders is rapidly becoming more acceptable. In 2021, 86% of respondents either “strongly agreed” or “somewhat agreed” that collaboration with other shareholders is an effective way to influence boards, a significant increase compared to the 2018 survey result (12%).
Aside from poor financial performance, poor strategic decisions were the factor most likely to lead an investor to support an activist. When asked what ESG factors might lead them to support an activist, 66% of respondents identified a lack of response to an ESG shareholder resolution as the most pressing issue.
Last year the survey proposed a slightly different but similar question about how investors would seek to influence boards to pay more attention to ESG issues, and this option received only 21% support. It is notable that the support for this option has increased dramatically in 2021. This clearly reflects the overarching theme of investor responses this year: the increasingly sharp focus on climate change at a global level.
To see the full results of Morrow Sodali’s Institutional Investor Survey 2021, visit here .
ABOUT MORROW SODALI
Morrow Sodali is a leading provider of strategic advice and shareholder services to corporate clients around the world. The firm provides corporate boards and executives with strategic advice and services relating to corporate governance, shareholder and bondholder communication and engagement, capital markets intelligence, proxy solicitation, shareholder activism and mergers and acquisitions.
From headquarters in New York and London, and offices and partners in major capital markets, Morrow Sodali serves more than 700 corporate clients in 80+ countries, including many of the world’s largest multinational corporations. In addition to listed and private companies, its clients include financial institutions, mutual funds, ETFs, stock exchanges and membership associations.
For further information about Morrow Sodali, please visit www.morrowsodali.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005108/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
